Skip to main content
Clinical Trials/NCT05507255
NCT05507255CompletedNot Applicable

Effect of Aerobic Exercise on Diurnal Cortisol Pattern in Premenstrual Syndrome: A Randomized Controlled Trial

Cairo University1 site in 1 country28 target enrollmentStarted: February 1, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
28
Locations
1
Primary Endpoint
Diurnal cortisol pattern

Study Overview

Brief Summary

The aim of this study will be to investigate the effect of aerobic exercise on diurnal cortisol pattern in premenstrual syndrome.

Detailed Description

Premenstrual syndrome is manifested by recurrent emotional and depressive symptoms that may be associated with maladaptive coping with stress situations and the enhanced release of stress hormones, like cortisol hormone. Although previous studies revealed a flattened diurnal cortisol slope in women with PMS compared to healthy controls, there is no previous work on the effect of aerobic exercise on diurnal cortisol pattern in premenstrual syndrome. Therefore, this study will aim to investigate the effect of aerobic exercise participation on diurnal cortisol pattern in premenstrual syndrome.This trial will include two groups; group (A) will consist of 14 females who will receive relaxation training for 8 weeks, while group (B) will consist of 14 females who will receive the same relaxation training along with aerobic exercise for 8 weeks.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Masking Description

Random generator

Eligibility Criteria

Ages
18 Years to 23 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Sedentary, virginal, adult, non-smoker females suffering from premenstrual syndrome.
  • •They should have regular menstrual cycles (cycles of 21-35 days with a bleeding time of 3-10 days)
  • •They should have the following criteria in daily record of severity of problems in at least one of two consecutive menstrual cycles prior to treatment starting to confirm premenstrual syndrome diagnosis: a) more than three items have an average score over 3 during the luteal phase, and b) a luteal phase score is 30% more than a follicular phase score.
  • •No traumatic life events in the last 2 months before starting the study.
  • •Their age will be 18-23 years
  • •Their body mass index (BMI) will be less than 30 kg/m2.

Exclusion Criteria

  • •Menstrual problems (e.g. menorrhagia, metrorhagia and polycystic ovary disease).
  • •Cardio-respiratory, renal, neurological and pelvic inflammatory diseases, tumors, infections, anemia, diabetes, hypertension, asthma, rheumatoid arthritis, headache, migraine, thyroid or mental disorders.
  • •Participation at any other exercise training program during this study.
  • •Receiving any kind of medications, hormonal treatment or supplementation (vitamin, mineral or herbal supplement).

Arms & Interventions

Relaxation training

Active Comparator

Females will receive relaxation training, in the form of deep breathing, 3 days per week, for 8 weeks.

Intervention: Relaxation training (Other)

The same relaxation training plus an aerobic exercise program

Experimental

Females will receive the same relaxation training, in addition to 30 minutes of a moderate aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.

Intervention: Relaxation training (Other)

The same relaxation training plus an aerobic exercise program

Experimental

Females will receive the same relaxation training, in addition to 30 minutes of a moderate aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.

Intervention: An aerobic exercise program (Other)

Outcomes

Primary Outcomes

Diurnal cortisol pattern

Time Frame: 8 weeks

It will be evaluated through calculating the ratio of morning cortisol level to evening cortisol level for all participants at baseline and after 8 weeks of treatment.

Severity of premenstrual symptoms

Time Frame: 8 weeks

Severity of premenstrual symptoms of all participants will be measured through daily record of severity of problems (DRSP) at baseline and after 8 weeks of treatment.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Doaa A. Osman

Assistant Professor

Cairo University

Study Sites (1)

Loading locations...

Similar Trials